Why Big Pharma Is Suing Compounding Pharmacies Over Semaglutide and Tirzepatide
In recent months, major pharmaceutical companies have filed lawsuits against certain compounding pharmacies that are producing and selling versions of semaglutide and tirzepatide, the active pharmaceutical ingredients (APIs) in brand-name medications originally developed for the treatment of type 2 diabetes and, more recently, weight management.
At Strive Wellness Clinic, we believe in being fully transparent and helping our patients understand the rapidly evolving regulatory and pharmaceutical landscape—especially when it impacts their health choices.
What Are Semaglutide and Tirzepatide?
Semaglutide and tirzepatide are both GLP-1 receptor agonists, a class of medications that mimic natural gut hormones to regulate blood sugar and appetite. They’ve become well known for their off-label use in weight management—often prescribed under supervision by medical providers.
Why Are There Lawsuits?
Pharmaceutical companies such as Novo Nordisk and Eli Lilly, who developed the original, FDA-approved medications (sold under brand names such as Ozempic®, Wegovy®, and Mounjaro®), have taken legal action against some compounding pharmacies and telehealth providers.
The core issues include:
Patent protection: These medications are under patent, and brand-name manufacturers argue that compounded versions violate their exclusive rights.
Safety and FDA compliance: The FDA has warned about the use of non-pharmaceutical-grade semaglutide (such as semaglutide salts) in some compounded products, which may not meet federal safety standards.
Misleading advertising: Some providers have marketed these compounded medications using brand names, which is not allowed under current FDA and trademark law.
Why This Matters to You
At Strive Wellness Clinic, we do not sell or advertise any brand-name medications. We work with reputable pharmacies that comply with FDA guidelines, and when appropriate, we may prescribe compounded peptides or other ingredients that are legally available and medically indicated.
We believe in personalized medicine, patient education, and transparency. While compounded therapies are sometimes appropriate alternatives when a drug is on national shortage or unavailable, we are always cautious to avoid infringing on intellectual property rights or compromising patient safety.
Our Approach
We refer to medications by their generic names, when clinically necessary, and we:
Do not use brand names such as Wegovy®, Ozempic®, or Mounjaro® in our marketing.
Partner only with licensed, 503A and 503B compounding pharmacies that source ingredients responsibly.
Follow FDA guidance and ongoing litigation closely to ensure compliance and patient safety.
Final Thoughts
This legal landscape is still evolving. If you're considering any form of weight management support or GLP-1 therapy, it's critical to work with a provider who prioritizes safety, legality, and informed decision-making.
If you have questions about peptide therapy, GLP-1 medications, or compounded prescriptions, we’re here to help guide you—safely and legally.
Disclaimer: This blog is for educational purposes only and does not promote or advertise the sale of any specific pharmaceutical product. All treatment decisions should be made with your licensed medical provider.